DiaMedica Therapeutics Inc (DMAC) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of DiaMedica Therapeutics Inc stock $4.94, price $8.33, that is 40.7% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
DiaMedica Therapeutics Inc
DMAC · USFar too expensive (fair value 41% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range $1.13 – $10.77 · fair‑value band $3.70 – $6.17 · the $8.33 price screens above the $4.94 fair value. As of Nov 15, 2026.
Every Wednesday you see whether DiaMedica Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
Show moreShow less
Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.
DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Stock analysis
DiaMedica Therapeutics Inc (DMAC) currently trades at $8.33, while our estimate is $4.94, 41% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $3.70 (bear) to $6.17 (bull), the price of $8.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
DiaMedica Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$32.8M in FY2025.
Key figures
Market cap $449M Small · EPS (TTM) $−0.7500 · Return on equity −100% · Return on assets (EBIT) −44.7% (5-year average) · Free cash flow −$29.1M · Net cash $15.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, DMAC screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- BuyAb Trill10% owner1,061,277 shares at $7.19$7.6MNov 25, 2025
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare DiaMedica Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs DMAC |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs DMAC |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs DMAC |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs DMAC |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs DMAC |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs DMAC |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs DMAC |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs DMAC |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs DMAC |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs DMAC |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is DiaMedica Therapeutics Inc (DMAC) overvalued or undervalued?
What is the fair value of DMAC?
What is the quality score of DMAC?
What is the price target for DiaMedica Therapeutics Inc (DMAC)?
What is the DiaMedica Therapeutics Inc stock forecast for 2026?
What is the intrinsic value of DiaMedica Therapeutics Inc (DMAC)?
Is DiaMedica Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of DMAC?
How much is DiaMedica Therapeutics Inc worth?
What do the bullish and bearish scenarios say about DMAC?
How solid is the balance sheet of DiaMedica Therapeutics Inc (DMAC)?
How far is DMAC from its 52-week high?
Which stocks are comparable to DiaMedica Therapeutics Inc?
Is DiaMedica Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of DiaMedica Therapeutics Inc (DMAC)?
What should I pay attention to with DiaMedica Therapeutics Inc right now?
Key figures of DiaMedica Therapeutics Inc
How large is the market capitalisation of DiaMedica Therapeutics Inc (DMAC)?
What are the earnings per share of DiaMedica Therapeutics Inc (DMAC)?
What is the return on equity of DiaMedica Therapeutics Inc (DMAC)?
What is the EBIT return on assets of DiaMedica Therapeutics Inc (DMAC)?
How much free cash flow does DiaMedica Therapeutics Inc (DMAC) generate?
How much net cash does DiaMedica Therapeutics Inc (DMAC) hold?
Watch DiaMedica Therapeutics Inc in the live analysis
One click puts DiaMedica Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.